Serpentine supravenous hyperpigmentation (SSH) is a unique type of chemotherapy‐associated drug eruption, characterized by hyperpigmentation along the superficial venous network. Histopathology reveals an increase in melanin production without destruction of basal cells of the epidermis or dermal inflammatory infiltrate. Herein, we describe a patient who developed SSH after repeated intravenous infusions with carboplatin and vinorelbine; two medications that have been uncommonly reported in association with SSH previously.

No abstract

The aim of the present study was to investigate the potential effects of isotretinoin on the biliary system in patients with acne vulgaris receiving isotretinoin therapy. This was a preliminary retrospective study involving 40 patients with severe acne vulgaris who attended the dermatology clinic and were administered different doses (20 or 30 mg/day) of isotretinoin. Serum levels of AST, ALT, ALP, GGT, total bilirubin, direct bilirubin, and indirect bilirubin at the beginning and at the first month of therapy were scanned, recorded, and statistically analyzed. Total and indirect bilirubin levels at the first month of treatment in 30 patients, receiving isotretinoin at a dose of 20 mg/day, were significantly lower compared to the baseline values (p = .02 and p = .03, respectively), whereas AST and GGT serum levels were significantly higher (p = .003 and p = .006 respectively). No significant reduction in total and indirect bilirubin levels was detectable at the first month of treatment in 10 patients receiving isotretinoin at a dose of 30 mg/day; however, AST, ALP, and GGT levels were significantly elevated in these patients (p = .023; p = .004; and p = .001, respectively). To our knowledge, there is no previous study investigating the effects of isotretinoin on the biliary system, and, therefore, the present study is a preliminary one. Our findings implicate that low dose (20 mg/day) isotretinoin therapy can potentially reduce total and indirect bilirubin levels. Long‐term, large‐scale, prospective studies with patients receiving different doses of isotretinoin may provide more reliable information regarding the bilirubin lowering effects of isotretinoin and optimum dosing for achieving this clinical effect.

aim: Telogen effluvium(TE) in women is a common problem in dermatology and has multiple etiologic causes. Low iron stores can be a possible contributing factor in TE. Although etiopathogenesis is not fully understood, many studies show remarkable associations between various diseases and ABO blood groups. Genomewide association studies have reported alleles in the ABO locus to be associated with ferritin levels. We had done this study with TE patients to detect serum ferritin levels and to find this relation between blood groups. Material and Methods: Healthy people and patients with TE were included in this study. A total of 103 females who have telogen effluvium and 125 controls were included. Results: ABO blood group and Rhesus factor distribution in patients with TE and distribution of healthy donors were similar. There haven't any significant association between ferritin levels and blood groups in TE patients. Conclusion: There are many different causes in TE etiology, for this reason in our opinion, ferritin levels and other laboratory tests must be done. We conclude that there was no evocation between ABO blood groups, Rhesus factor and ferritin levels in TE, but this is the first study that can show this relationship and can be important for new studies which will be carried out in other centers with wider series.

Geographical tongue, also known as benign migratory glossitis or erythema migrans, is a benign dermatosis whose specific etiology is not known due to the disappearance of central erythematous and filiform papillaries surrounded by a hyperkeratotic ring forming the geographical shape on the tongue. The disease causes pain and burning sensation in patients particularly when they intake acidic and hot food.Nutritional deficiencies were rarely encountered in the research. In treatment, topical corticosteroids may be recommended for symptomatic relief (Jacob, 2016;Khan, 2018).It was determined that the 55-year-old female patient, who was diagnosed polymyositis and prescribed systemic corticosteroids and azathioprine, started at the same time, applied to our clinic with the complaints of centralized, peripheral hyperkeratotic white plaques that give a feeling of burning against widespread, erythematic, hot, and acidic food. It did not benefit from the topical treatments that she used from time to time for a long time. In the dermatological examination of the patient, the widespread periphery, starting from the ventral to the dorsal root, surrounded by white hyperkeratotic rings, consisting of plaques characterized by the disappearance of erythematous, filiform papillaries were seen (Figure 1). The nutritional tests of the patient were evaluated as normal. There was emotional stress that due to the role of chronic illness in the patient. Initially 2 × 25 mg pregabalin treatment started. In the first month of the treatment the lesions recovered 80-90%, and burning sensation diminished too (Figure 2). The treatment of the patient was readjusted to 1 × 25 mg/day. In the second month of the treatment, there was no increase in lesions; it was observed that there was some new healing and total regression of the subjective symptoms (Figure 3). Pregabalin, is an analogue of gamma amino butyric acid (GABA). It is the calcium canal ligand of pregabalin α2-δ and it is strongly attached to FIGURE 1 Geographical tongue before treatmentFIGURE 2 The first month of pregabalin treatment FIGURE 3 The second month of pregabalin treatment

Aim: Chronic urticaria is a condition that requires long-term treatment. In recent years, many countries have created their own guides to evaluate urticaria diagnosis and treatment approaches in an algorithm. In this study, we aimed to evaluate the distribution of patients with chronic urticaria treated in our clinic according to the treatment algorithm the "Turkey Urticaria Diagnosis and Treatment Guide" Material and Method: The files of the patients who applied to the dermatology clinic of our hospital and were followed up and treated with a diagnosis of chronic urticaria were investigated. Results: A total of 102 patients with chronic urticaria were included in the study. According to this guide, 17.6% of patients responded with standard dose antihistamine therapy, while the antihistamine dose given in 15.7% of patients was increased. The antihistamine treatment of 5.7% of patients was replaced by a different group of antihistamines at the same dose as the previous one. 52% of patients responded to omalizumab 300 mg/subcutaneous treatment every 28 days. However, 7.8% of the patients received omalizumab treatment every 14 days or cyclosporine treatment was required to be added to omalizumab treatment. Response to other treatments other than standard treatments was received in 1% of patients. Conclusion:We believe that our study will facilitate predicting the treatment responses of patients in clinical practice by shedding light on the distribution of chronic urticaria patients according to the treatment algorithm.

No abstract